{
    "info": {
        "nct_id": "NCT05371964",
        "official_title": "An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis",
        "inclusion_criteria": "* Diagnosis of primary myelofibrosis (PMF) according to the revised World Health Organization (WHO) criteria or post-essential thrombocythemia-MF or post-polycythemia vera according to the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria.\n* Dynamic International Prognostic Scoring System (DIPSS) intermediate-1, intermediate-2 or high-risk MF.\n* Candidate for ruxolitinib treatment:\n\n  1. Part 1 participants only: On ruxolitinib treatment for at least 12 weeks with at least 4 consecutive weeks immediately prior to enrollment at a stable dose.\n  2. Part 2 participants only: Candidate for ruxolitinib treatment as assessed by the investigator and has not previously been treated with a JAK inhibitor.\n* Clinical signs/symptoms of MF demonstrated by one of the following:\n\n  1. Measurable splenomegaly demonstrated by either a palpable spleen measuring ≥5 cm below the left costal margin or a spleen volume ≥450 cm^3 by MRI or CT,\n  2. active symptoms of MF on the MFSAF v4.0.\n* Ineligible for or unwilling to undergo hematopoietic stem cell transplant at time of study entry.\n* Hematology laboratory test values within protocol defined limits.\n* Biochemical laboratory test values within protocol defined limits.\n* Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2.\n* Participants should follow protocol defined contraceptives procedures.\n* A woman of childbearing potential must have a negative serum or urine pregnancy test at screening.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Peripheral blood blast count of ≥10% or bone marrow blast count of ≥10%.\n* Prior treatment with JAK inhibitor.\n* Known allergies, hypersensitivity, or intolerance to imetelstat or ruxolitinib or excipients.\n* Prior treatment with imetelstat.\n* Major surgery within 28 days prior to enrollment.\n* Any investigational drug regardless of class or mechanism of action, hydroxyurea, chemotherapy, immunomodulatory or immunosuppressive therapy, corticosteroids >30 mg/day prednisone or equivalent ≤14 days prior to enrollment.\n* Prior history of hematopoietic stem cell transplant.\n* Prior history of partial or complete splenectomy.\n* Diagnosis or treatment for malignancy other than MF, except:\n\n  * Malignancy treated with curative intent and with no known active disease present for ≥3 years before enrollment.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Adequately treated cervical carcinoma in situ without evidence of disease.\n* Clinically significant cardiovascular disease.\n* Known history of human immunodeficiency virus (HIV) or any uncontrolled active systemic infection requiring IV antibiotics.\n* Active systemic hepatitis infection requiring treatment or any known acute or chronic liver disease unless related to MF. Carriers of hepatitis virus are permitted to enter the study.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Biochemical laboratory test values within protocol defined limits.",
            "criterions": [
                {
                    "exact_snippets": "Biochemical laboratory test values within protocol defined limits",
                    "criterion": "biochemical laboratory test values",
                    "requirements": [
                        {
                            "requirement_type": "within protocol defined limits",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Candidate for ruxolitinib treatment:",
            "criterions": [
                {
                    "exact_snippets": "Candidate for ruxolitinib treatment",
                    "criterion": "ruxolitinib treatment candidacy",
                    "requirements": [
                        {
                            "requirement_type": "candidacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hematology laboratory test values within protocol defined limits.",
            "criterions": [
                {
                    "exact_snippets": "Hematology laboratory test values within protocol defined limits",
                    "criterion": "hematology laboratory test values",
                    "requirements": [
                        {
                            "requirement_type": "within protocol defined limits",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. active symptoms of MF on the MFSAF v4.0.",
            "criterions": [
                {
                    "exact_snippets": "active symptoms of MF on the MFSAF v4.0.",
                    "criterion": "myelofibrosis (MF) symptoms",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "assessment tool",
                            "expected_value": "MFSAF v4.0"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinical signs/symptoms of MF demonstrated by one of the following:",
            "criterions": [
                {
                    "exact_snippets": "Clinical signs/symptoms of MF",
                    "criterion": "clinical signs or symptoms of myelofibrosis (MF)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2",
                    "criterion": "Eastern Cooperative Oncology Group Performance Status score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ineligible for or unwilling to undergo hematopoietic stem cell transplant at time of study entry.",
            "criterions": [
                {
                    "exact_snippets": "Ineligible for ... hematopoietic stem cell transplant",
                    "criterion": "hematopoietic stem cell transplant eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to undergo hematopoietic stem cell transplant",
                    "criterion": "willingness to undergo hematopoietic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Dynamic International Prognostic Scoring System (DIPSS) intermediate-1, intermediate-2 or high-risk MF.",
            "criterions": [
                {
                    "exact_snippets": "Dynamic International Prognostic Scoring System (DIPSS) intermediate-1, intermediate-2 or high-risk MF",
                    "criterion": "DIPSS risk category for myelofibrosis (MF)",
                    "requirements": [
                        {
                            "requirement_type": "category",
                            "expected_value": [
                                "intermediate-1",
                                "intermediate-2",
                                "high-risk"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Measurable splenomegaly demonstrated by either a palpable spleen measuring ≥5 cm below the left costal margin or a spleen volume ≥450 cm^3 by MRI or CT,",
            "criterions": [
                {
                    "exact_snippets": "palpable spleen measuring ≥5 cm below the left costal margin",
                    "criterion": "palpable spleen",
                    "requirements": [
                        {
                            "requirement_type": "size_below_left_costal_margin",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "spleen volume ≥450 cm^3 by MRI or CT",
                    "criterion": "spleen volume",
                    "requirements": [
                        {
                            "requirement_type": "volume",
                            "expected_value": {
                                "operator": ">=",
                                "value": 450,
                                "unit": "cm^3"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "MRI",
                                "CT"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Part 2 participants only: Candidate for ruxolitinib treatment as assessed by the investigator and has not previously been treated with a JAK inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "Candidate for ruxolitinib treatment as assessed by the investigator",
                    "criterion": "candidate for ruxolitinib treatment",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_by_investigator",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has not previously been treated with a JAK inhibitor",
                    "criterion": "prior treatment with JAK inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Part 1 participants only: On ruxolitinib treatment for at least 12 weeks with at least 4 consecutive weeks immediately prior to enrollment at a stable dose.",
            "criterions": [
                {
                    "exact_snippets": "On ruxolitinib treatment for at least 12 weeks",
                    "criterion": "ruxolitinib treatment duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 4 consecutive weeks immediately prior to enrollment at a stable dose",
                    "criterion": "ruxolitinib stable dose duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "dose stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A woman of childbearing potential must have a negative serum or urine pregnancy test at screening.",
            "criterions": [
                {
                    "exact_snippets": "A woman of childbearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative serum or urine pregnancy test at screening",
                    "criterion": "pregnancy test result at screening",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "serum",
                                "urine"
                            ]
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of primary myelofibrosis (PMF) according to the revised World Health Organization (WHO) criteria or post-essential thrombocythemia-MF or post-polycythemia vera according to the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of primary myelofibrosis (PMF) according to the revised World Health Organization (WHO) criteria",
                    "criterion": "primary myelofibrosis diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "revised World Health Organization (WHO) criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "post-essential thrombocythemia-MF ... according to the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria",
                    "criterion": "post-essential thrombocythemia myelofibrosis diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "post-polycythemia vera ... according to the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria",
                    "criterion": "post-polycythemia vera myelofibrosis diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants should follow protocol defined contraceptives procedures.",
            "criterions": [
                {
                    "exact_snippets": "Participants should follow protocol defined contraceptives procedures.",
                    "criterion": "contraceptive procedures",
                    "requirements": [
                        {
                            "requirement_type": "adherence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Clinically significant cardiovascular disease.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis or treatment for malignancy other than MF, except:",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis or treatment for malignancy other than MF",
                    "criterion": "malignancy other than MF",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior history of partial or complete splenectomy.",
            "criterions": [
                {
                    "exact_snippets": "Prior history of partial or complete splenectomy",
                    "criterion": "splenectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "partial",
                                "complete"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with imetelstat.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with imetelstat",
                    "criterion": "prior treatment with imetelstat",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequately treated cervical carcinoma in situ without evidence of disease.",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated cervical carcinoma in situ",
                    "criterion": "cervical carcinoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "without evidence of disease",
                    "criterion": "evidence of disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malignancy treated with curative intent and with no known active disease present for ≥3 years before enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Malignancy treated with curative intent",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_intent",
                            "expected_value": "curative"
                        }
                    ]
                },
                {
                    "exact_snippets": "no known active disease present for ≥3 years before enrollment",
                    "criterion": "active disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration_since_last_active_disease",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of human immunodeficiency virus (HIV) or any uncontrolled active systemic infection requiring IV antibiotics.",
            "criterions": [
                {
                    "exact_snippets": "Known history of human immunodeficiency virus (HIV)",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any uncontrolled active systemic infection requiring IV antibiotics",
                    "criterion": "active systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring IV antibiotics"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated non-melanoma skin cancer",
                    "criterion": "non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "lentigo maligna without evidence of disease",
                    "criterion": "lentigo maligna",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": "without evidence of disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with JAK inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with JAK inhibitor",
                    "criterion": "prior treatment with JAK inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior history of hematopoietic stem cell transplant.",
            "criterions": [
                {
                    "exact_snippets": "Prior history of hematopoietic stem cell transplant",
                    "criterion": "hematopoietic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Peripheral blood blast count of ≥10% or bone marrow blast count of ≥10%.",
            "criterions": [
                {
                    "exact_snippets": "Peripheral blood blast count of ≥10%",
                    "criterion": "peripheral blood blast count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bone marrow blast count of ≥10%",
                    "criterion": "bone marrow blast count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active systemic hepatitis infection requiring treatment or any known acute or chronic liver disease unless related to MF. Carriers of hepatitis virus are permitted to enter the study.",
            "criterions": [
                {
                    "exact_snippets": "Active systemic hepatitis infection requiring treatment",
                    "criterion": "systemic hepatitis infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any known acute or chronic liver disease unless related to MF",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "relation to MF",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Carriers of hepatitis virus are permitted to enter the study",
                    "criterion": "hepatitis virus carrier status",
                    "requirements": [
                        {
                            "requirement_type": "carrier status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any investigational drug regardless of class or mechanism of action, hydroxyurea, chemotherapy, immunomodulatory or immunosuppressive therapy, corticosteroids >30 mg/day prednisone or equivalent ≤14 days prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Any investigational drug ... ≤14 days prior to enrollment.",
                    "criterion": "investigational drug use",
                    "requirements": [
                        {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hydroxyurea ... ≤14 days prior to enrollment.",
                    "criterion": "hydroxyurea use",
                    "requirements": [
                        {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "chemotherapy ... ≤14 days prior to enrollment.",
                    "criterion": "chemotherapy use",
                    "requirements": [
                        {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "immunomodulatory or immunosuppressive therapy ... ≤14 days prior to enrollment.",
                    "criterion": "immunomodulatory or immunosuppressive therapy use",
                    "requirements": [
                        {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "corticosteroids >30 mg/day prednisone or equivalent ≤14 days prior to enrollment.",
                    "criterion": "corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "mg/day prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known allergies, hypersensitivity, or intolerance to imetelstat or ruxolitinib or excipients.",
            "criterions": [
                {
                    "exact_snippets": "Known allergies, hypersensitivity, or intolerance to imetelstat",
                    "criterion": "allergy/hypersensitivity/intolerance to imetelstat",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known allergies, hypersensitivity, or intolerance to ... ruxolitinib",
                    "criterion": "allergy/hypersensitivity/intolerance to ruxolitinib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known allergies, hypersensitivity, or intolerance to ... excipients",
                    "criterion": "allergy/hypersensitivity/intolerance to excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 28 days prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 28 days prior to enrollment.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}